NCT03635125已完成4 期
A Prospective, Randomized, Open-Label, Active-Comparator, Blinded-Endpoint, 12-week Forced-Titration Study of the Efficacy and Safety of Nebivolol Verses Metoprolol in Hypertensive Subjects Taking Amlodipine
Trinity Hypertension & Metabolic Research Institute1 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2010年8月30日最近更新:
适应症
干预措施
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 40
- 试验地点
- 1
- 主要终点
- Mean Change from baseline in trough Diastolic Blood Pressure
研究概览
简要总结
Study is to evaluate the effect of Nebivolol to treat high blood pressure compared to an already approved drug, Metoprolol ER with background treatment of Amlodipine.
详细描述
Open-label, single center study consisting of a 2 to 4 week baseline washout phase, a 12-week Amlodipine background treatment phase followed by a 4-week Low Dose Nebivolol/Metoprolol Treatment phase and a 4-week High Dose Nebivolol/Metoprolol Treatment Phase.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Health Services Research
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Capable of reading, comprehending the consent process and providing written informed consent to participate in the study.
- •Male or female equal/over 18 years of age.
- •Stage I-II hypertension defined as a baseline mean seated cuff Diastolic blood pressure of equal/over 95 mmHg and equal/less 115 mmHg and Systolic blood pressure equal/less to 180 mmHg at two consecutive qualifying visits during the placebo run in period.
- •Arm circumference less 45 cm
- •Compliance with single blind placebo capsules between V1-4 of 80-120%.
- •Women may be enrolled if all three of the following criteria are met:
- •Have a negative serum pregnancy test at screening
- •Are not breastfeeding
- •Do not plan to become pregnant during the study and if one of the three criteria is met:
- •Have had a hysterectomy or tubal ligation at least 6 months prior to signing the informed consent form
- •Have been postmenopausal for at least 1 year
- •Are of childbearing potential and will practice one the following methods of birth control throughout the study: oral, patch, injectable, or implantable hormone contraception, intrauterine device, diaphragm plus spermicide or female condom plus spermicide. Abstinence, partner's vasectomy are not acceptable methods of contraception.
排除标准
- •Known allergy or hypersensitivity to Beta Blockers.
- •Known allergy or hypersensitivity to Calcium Channel Blockers.
- •Patients with severe hypertension (mean seated cuff Diastolic blood pressure > 115 mmHg or mean seated Systolic blood pressure >180 mmHg) or any form of secondary hypertension.
- •Patients within the past 6 months with a history of hypertensive encephalopathy, stroke or transient ischemic attack.
- •Patients within the last 6 months with a history of myocardial infarction, percutaneous trans luminal coronary revascularization, coronary bypass graft, valvular surgery or unstable angina.
- •Patients with evidence of resting bradycardia (<50 bpm) via palpation.
- •Patients with a history of heart block greater than First Degree Sino atrial Block. Wolff-Parkinson-White Syndrome, Sick Sinus Syndrome, Atrial Fibrillation, Atrial Flutter, Congestive Heart Failure, or other manifestations of clinically significant cardiac valvular disease.
- •Patients with hemodynamically significant cardiac valvular disease.
- •Patients with evidence of significant chronic renal impairment as indicated by a serum creatinine of > 2.5mg/dL
- •Patients with evidence of liver disease as indicated by AST (SGOT) or ALT (SGPT) > 2.5 times or total bilirubin > 1.5 times, the upper limit of the laboratory normal range.
- •Patients who demonstrate other laboratory test values deviating from the Normal range which are considered to be clinically significant by the investigator.
- •Patient with a history or presence of gastrointestinal disease which may interfere with drug absorption.
- •Patients with insulin and non-insulin dependent diabetes mellitus not controlled on diet, insulin or oral hypoglycemic as defined by a HgA1c >
- •Severe psychological or emotional condition which may interfere with participation in the study.
- •History of or current use of illicit drugs or alcohol abuse.
- •Participation in a clinical trial and taking any investigation drug within 30 days prior to enrolling into the study (Screening Visit).
- •A physical condition that would limit accurate BP measurement.
- •Inability to swallow a tablet or capsule.
- •History of moderate or sever asthma or Chronic obstructive pulmonary disease.
- •Any other medical condition which, in the Investigator's opinion, may render the patient unable to complete the study or which would interfere with optimal participation in the study or produce significant risk to the patient.
研究组 & 干预措施
Low Dose Treatment Phase-Nebivolol I
Active Comparator
4-week low dose Nebivolol10 mg/Metoprolol 50 mg treatment phase
干预措施: Nebivolol I (Drug)
Low Dose Treatment Phase-Nebivolol I
Active Comparator
4-week low dose Nebivolol10 mg/Metoprolol 50 mg treatment phase
干预措施: Nebivolol II (Drug)
High dose treatment Phase-Nebivolol II
Active Comparator
4-week High dose Nebivolol 20 mg/Metoprolol 100mg treatment phase
干预措施: Nebivolol I (Drug)
High dose treatment Phase-Nebivolol II
Active Comparator
4-week High dose Nebivolol 20 mg/Metoprolol 100mg treatment phase
干预措施: Nebivolol II (Drug)
Baseline Washout Phase
Other
2 to 4 week Baseline Washout Phase
干预措施: Baseline Washout Phase (Other)
结局指标
主要结局
Mean Change from baseline in trough Diastolic Blood Pressure
时间窗: 4 and 8 weeks of treatment
Mean change by millimeters of mercury from baseline in trough Diastolic Blood Pressure
Mean Change in Edema Measurement
时间窗: 4 and 8 weeks of treatment
Mean change in edema measurement by water immersion of treatment in millimeters of water
次要结局
- Percentage of subjects achieving Blood pressure goals(4 and 8 weeks of treatment)
- Change from baseline in trough Systolic blood pressure of treatment.(4 and 8 weeks of treatment)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
4 期
The Effect of Nebivolol in Hypertensive Patients With Coronary Artery DiseaseHypertensionCoronary Artery DiseaseNCT00673075Forest Laboratories39
已完成
4 期
Efficacy and Safety of Nebivolol (Added to Lisinopril or Losartan) in Hypertensive PatientsHypertensionNCT00734630Forest Laboratories491
已完成
3 期
Safety and Efficacy of Nebivolol in the Treatment of Hypertension in African AmericansHypertensionNCT00145210Mylan Bertek Pharmaceuticals630
已完成
不适用
Effects of Nebivolol on Exercise Tolerance and Left Ventricular Systolic and Diastolic FunctionHypertensionNCT01056718Mercy Research53
已完成
4 期
Olmesartan Comparison to Losartan in Hypertensive SubjectsHypertensionNCT00949884Daiichi Sankyo941